P361 Laboratory criteria of infliximab therapy inefficiency in children with IBD
A. Potapov*1, T. Radigina2, S. Petrichuk2, D. Gerasimova2, A. Illarionov1,3, A. Anushenko1, T. Erlikh-Fox4
1National Medical Research Center for Children's Health, Gastroenterology and Hepatology, Moscow, Russian Federation, 2National Medical Research Center for Children's Health, Laboratory of Experimental Immunology and Virology, Moscow, Russian Federation, 3Sechenov First Moscow State Medical University, Department of Peliatrics and Rheumatology, Moscow, Russian Federation, 4National Medical Research Center for Children's Health, Cytochemical Research Center, Moscow, Russian Federation
Our aim was to identify the value of the laboratory criteria such as residual level of infliximab (IFX) in blood, antibodies to IFX and circulating cytokine levels in the prognosis of the effectiveness of the therapy in children with IBD.
Were included in the study 75 children with IBD (31 patients with UC and 44 patients with CD) aged 4–18 years who were treated with IFX. Clinical response was evaluated according PUCAI (UC) and PCDIA (CD) scores. Blood samples were taken 8 weeks after the last infusion of IFX. Residual levels of IFX (Q-IFX) in serum and IFX antibodies (ATI) were assessed by enzyme immunoassay using Shikari Q-INFLIXI, Q-ATI (Turkey) kits. The cytokine levels were measured by multiplex analysis using HumanThl7 MagneticBead Panel (MilliplexMapKit, Germany). Evaluation of the statistical significance was performed using nonparametric Mann–Whitney test and ROC-analysis.
There were observed increase in the inflammatory activity according to PUCAI and PCDIA scores (
The reduction of the Q-IFX in children with UC below 2.55 μg/ml and in children with CD below 2.21 μg/ml, leads to the decrease of the therapy effect and can adduct to the exacerbation of the disease. These findings correlate with the results obtained in adults (>2 µg/ml, C. Moore